Screening & Prevention: The Checklist
Screening finds disease early. It also manufactures patients. The evidence-backed schedule for midlife women, the honest cost column most checklists leave out, and why the biggest prevention wins still live outside the clinic.
What the evidence supports
- Cervical, colorectal, breast, and lung screening each reduce cancer-specific mortality in randomized or high-quality observational evidence.
- Blood pressure, lipid, and glucose checks catch the slow diseases — cardiovascular and metabolic — that kill more women than any screen-detected cancer.
- False positives, anxiety, and overdiagnosis are real, quantifiable costs that should shape — not veto — screening decisions.
What remains uncertain
- Mammography's optimal start age and interval — major guideline bodies genuinely disagree, and both sides cite the same trials.
- The precise magnitude of overdiagnosis is hard to estimate; models disagree, and it varies by test and by age.
- Whether newer tests (multi-cancer early detection blood tests, for example) help or harm — we don't know yet.
Evidence last reviewed: August 13, 2026. Conclusions may change as new research is published.
the prevention checklist
Screening Is a Trade, Not a Virtue
There's a default assumption baked into how we talk about screening: more tests, earlier, is always better. The evidence says otherwise. Every test trades real benefits — earlier treatment, fewer deaths — against real costs: false positives, anxiety, biopsies that find nothing, and overdiagnosis, the detection of disease that would never have caused symptoms or shortened life. A screen that finds such a cancer doesn't save a life; it converts a healthy woman into a patient.
The honest numbers on the trade: a woman getting annual mammograms for ten years has roughly a coin-flip chance of at least one false-positive recall — a callback, extra imaging, and often a biopsy that turns out benign. Estimates of breast cancer overdiagnosis typically land around 10–20% of screen-detected cases. None of this makes mammography a bad deal — the same trials that document the false positives show breast cancer mortality falling in screened populations. It makes screening risk arithmetic: the right question is never "why not test?" but "for whom, at what age, how often — and what happens to the false positives?"
The Schedule, Test by Test
The table below is the average-risk baseline — the schedule the major guideline bodies (USPSTF, ACS, ACOG) largely agree on. "Average risk" matters: family history, genetics, and personal medical history move every row. The honest note column is the part most checklists omit.
| Test | When | Frequency | The honest note |
|---|---|---|---|
| 🫀 Blood pressure | Every checkup, from any age | At least yearly; home readings too | The single highest-value measurement in the room — cheap, silent, and directly actionable via the Blood Pressure topic |
| 🧪 Lipids & HbA1c | From ~40s, earlier with risk factors | Every ~5 years; more often with risk | Catches the slow metabolic diseases that out-kill breast cancer — interpretation in the Lipid Panel topic |
| 🎀 Mammogram | 40–74 (USPSTF); some bodies say start at 45 | Every 1–2 years — biennial per USPSTF | The start age and interval debate is real; the false-positive coin flip is the price of the lives saved |
| 🌸 Cervical / HPV testing | 25–65 | HPV test every 5 years (or Pap every 3) | The clearest win in the list — cervical cancer incidence collapsed wherever screening took hold |
| 🩺 Colorectal | 45–75 | Colonoscopy every 10 yrs, or FIT yearly | The 45 start is new (2021); any offered modality beats none — the best test is the one you'll actually do |
| 🦴 Bone density (DEXA) | 65+; earlier with risk factors | As indicated by results and risk | Earlier if early menopause, low body weight, smoking, steroid use, or fracture history — full story in the Bone Health topic |
| 🫁 Lung CT (low-dose) | 50–80, with 20+ pack-year smoking history | Yearly while eligible | Only for the smoking-history group — for everyone else the false positives outweigh the benefit |
Two rows deserve the longer story. Mammography: the USPSTF recommends biennial screening from 40 to 74, while other groups favor annual screening starting later — and both cite the same randomized trials, weighting the same false-positive and overdiagnosis data differently. The defensible position for an individual woman is shared decision-making: know your risk (family history, breast density, prior biopsies), know the trade, and choose with your clinician. Colorectal: the starting age moved down to 45 because colorectal cancer is rising in younger adults, and screening in that window is now judged worth the trade. If colonoscopy feels like too much, an annual FIT stool test is a legitimate, evidence-backed alternative — its only weakness is that people skip years.
The Genetic Branch: When Family History Changes the Math
About 1 in 400 women carries a BRCA1 or BRCA2 mutation — roughly 1 in 40 among women of Ashkenazi Jewish ancestry. These mutations raise lifetime breast cancer risk to the range of 55–70% and ovarian cancer risk to 20–45%, which is why the standard screening schedule above is not the right schedule for carriers or for women with strong family histories. The table below is the pattern recognition clinicians use to decide who should talk to a genetic counselor.
| Family pattern | What it suggests |
|---|---|
| Breast cancer before 50 in a close relative | Worth a genetics conversation — early onset is the strongest single flag |
| Ovarian or pancreatic cancer in the family | Both track with BRCA mutations even without breast cancer in the family |
| Male breast cancer | Rare — and strongly associated with BRCA2 |
| Several relatives on one side with related cancers | A pattern, not a coincidence — genetics referral is reasonable |
| Ashkenazi Jewish ancestry plus any of the above | Carrier frequency is roughly 10× the general population |
If two or more of these flags describe your family, the next step is a clinician conversation — genetic counseling comes before any direct-to-consumer test, because interpretation (what a negative result does and doesn't rule out) matters more than the raw data. For women flagged as high-risk, the toolkit changes: earlier and more frequent breast imaging, sometimes MRI, and risk-reducing options that have no place in the average-risk schedule.
The Lifestyle Layer Does the Heavy Lifting
Here's the framing that matters most, and it's the reason this topic closes the Women's Health series rather than opening it: screening catches disease; prevention prevents it. Every mortality line in the table above is moved far more by what happens between checkups than by the checkup itself. The cardiovascular and metabolic diseases that kill most women respond to the boring levers documented across this site — sleep, strength training, nutrition, stress, relationships — and the most under-appreciated prevention tool in this entire context layer is the one you keep at home: the Quarterly Audit protocol, which turns blood pressure, waist circumference, glucose trends, and sleep quality into a four-times-a-year home screening system that costs nothing and catches drift years before a clinic test would.
The honest hierarchy: the clinic schedule in the table above is worth doing — the mortality benefits are real. But the annual exam should be the backstop, not the plan. A woman who gets every screen on schedule but skips sleep, strength, and stress management has traded the largest prevention levers for the smallest ones. The full picture — cardiovascular risk through the transition, bone's silent erosion, strength as the buffer — lives in the topics that precede this one. This checklist is the safety net; the pillars are the prevention.
🩺 The questions to ask before any screen
Before consenting to a test you don't obviously need, three questions change the conversation: What's my absolute risk without this screen? What happens to the false positives — how many callbacks, scans, and biopsies stand behind each cancer found? And what would we do differently if it came back positive? A screen whose positive result you wouldn't act on is a screen that can only cost you. That single question has saved more women from pointless procedures than any guideline.
The Bottom Line
- Screening is a trade, not a virtue — the schedule below is worth doing because the benefits are real, and worth doing on schedule because the harms grow with excess.
- The average-risk schedule: blood pressure yearly, mammograms biennially from age forty, HPV testing every five years, colorectal screening from the mid-forties, bone density at sixty-five (earlier with risk), lung CT only with a smoking history.
- Family history changes the math — early breast cancer, ovarian cancer, or male breast cancer in the family earns a genetics referral before any at-home test.
- The lifestyle layer is the prevention toolkit — screening catches; the ten pillars prevent, and the quarterly audit is the home version of this checklist.
Go Deeper: Subtopics
- 🔎 The decade-by-decade screen map — what to check at 40, 50, 60, 70 and why. Read it →
- 🔎 Cancer screening, current — mammography, cervical, colorectal: the age windows and the honest debates. Read it →
- 🔎 Bone & heart screening together — the transition's paired risks and the DEXA + lipid timing. Read it →
- 🔎 The symptom-advocacy guide — how to get atypical symptoms taken seriously. Read it →
- 🔎 Building the annual appointment — turning the checklist into one efficient yearly visit (links Quarterly Audit). Read it →
Related Topics
- U.S. Preventive Services Task Force, "Screening for breast cancer" (2024)
- Fontham et al., "Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society," CA: A Cancer Journal for Clinicians (2020)
- U.S. Preventive Services Task Force, "Screening for colorectal cancer" (2021)
- U.S. Preventive Services Task Force, "Screening for osteoporosis to prevent fractures" (2025)
- National Lung Screening Trial Research Team, "Reduced lung-cancer mortality with low-dose computed tomographic screening," New England Journal of Medicine (2011)
- Elmore et al., "Ten-year risk of false positive screening mammograms and clinical breast examinations," New England Journal of Medicine (1998)